Related Experiment Video
Updated: Oct 20, 2025
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection
Natalia Lattanzio1, Cristina Acosta-Diaz1, Ricardo J Villasmil1
1Internal Medicine, Sarasota Memorial Hospital, Florida State University College of Medicine, Sarasota, USA.
Insights
COVID-19 convalescent plasma (CCP) treatment effectiveness was studied in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This research characterized longitudinal biologic response and clinical outcomes to define an effective therapeutic window for CCP administration.
Area of Science:
- Infectious Diseases
- Hematology
- Immunology
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, has resulted in millions of deaths globally.
- COVID-19 convalescent plasma (CCP) received emergency use authorization for treating SARS-CoV-2 infection.
- A defined therapeutic window for CCP administration was lacking.
Purpose of the Study:
- To characterize the longitudinal biologic response in COVID-19 patients treated with CCP.
- To define the effective therapeutic window for CCP administration.
- To evaluate clinical outcomes, including discharge to home/home health, in patients receiving CCP.
Main Methods:
- Longitudinal characterization of biologic response in COVID-19 patients receiving CCP.
- Analysis of clinical outcomes, with a primary focus on discharge disposition.
- Evaluation of the relationship between CCP administration timing and patient outcomes.
Main Results:
- Biologic responses to CCP treatment were longitudinally characterized.
- Clinical outcomes, including discharge to home/home health, were assessed in treated patients.
- Data were collected to inform the effective therapeutic window for CCP.
Conclusions:
- Characterization of longitudinal biologic response and clinical outcomes provides insights into CCP effectiveness.
- Defining the therapeutic window for CCP is crucial for optimizing SARS-CoV-2 treatment strategies.
- Further research can refine CCP administration protocols based on these findings.
Abstract:
On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic window for CCP administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP. Primary outcome was discharged to home/home health.
